CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The IMMPACT project focuses on validating a serum biomarker signature for the early diagnosis of pancreatic cancer using advanced antibody microarray technology. This aims to enable accurate detection of cancer at an asymptomatic stage, improving patient outcomes.
The IMMPACT project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer.
The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB.
The underlying technology is affinity proteomics.
The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer.
The initial retrospective clinical studies have confirmed that the biomarker signatur…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
